mardepodect mardepodect mardepodect (developmental code name pf-2545920) is a drug which was developed by pfizer for the treatment of schizophrenia. it acts as a phosphodiesterase inhibitor selective for the pde10a subtype. the pde10a enzyme is expressed primarily in the brain, mostly in the striatum, nucleus accumbens and olfactory tubercle, and is thought to be particularly important in regulating the activity of dopamine-sensitive medium spiny neurons in the striatum which are known to be targets of conventional antipsychotic drugs. older pde10a inhibitors such as papaverine have been shown to produce antipsychotic effects in animal models, and more potent and selective pde10a inhibitors are a current area of research for novel antipsychotic drugs which act through a different pathway to conventional dopamine or 5-ht2a antagonist drugs and may have a more favourable side effects profile. mardepodect is currently one of the furthest advanced pde10a inhibitors in development and has progressed through to phase ii clinical trials in humans. in 2017, development of mardepodect for the treatment of schizophrenia and huntington's disease was discontinued. mardepodectclinical dataother namespdf-2545920atc codenonelegal statuslegal status investigational identifiers iupac name 2-(4-(1-methyl-4-pyridin-4-yl-1h-pyrazol-3-yl)phenoxymethyl)quinoline cas number898562-94-2 npubchem cid11581936drugbankdb08387 nchemspider9756702 nuniir9y8ey0g42keggd11171chemblchembl1642569 nchemical and physical dataformulac25h20n4omolar mass392.462 g·mol−13d model (jsmol)interactive image smiles n3c1ccccc1ccc3coc5ccc(cc5)-c2nn(c)cc2-c4ccncc4 inchi inchi=1s/c25h20n4o/c1-29-16-23(18-12-14-26-15-13-18)25(28-29)20-7-10-22(11-8-20)30-17-21-9-6-19-4-2-3-5-24(19)27-21/h2-16h,17h2,1h3 nkey:azexwhkommaspa-uhfffaoysa-n n ny (what is this?) (verify)